Anthrax vaccine (third generation) - Altimmune

Drug Profile

Anthrax vaccine (third generation) - Altimmune

Alternative Names: Lyophilized recombinant protective antigen anthrax vaccine; Lyophilized rPA anthrax vaccine; SparVax-L

Latest Information Update: 21 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avecia
  • Developer Altimmune
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anthrax

Most Recent Events

  • 15 May 2018 Phase-II clinical trials in Anthrax (Prevention) in USA (Parenteral) before May 2018
  • 12 Mar 2018 Pharmacodynamics data from a preclinical trial in Anthrax released by Altimmune
  • 06 Mar 2018 Preclinical development is ongoing USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top